Stay updated with breaking news from Philogen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Sun Pharma s partner, Philogen, has reported positive results in late-stage clinical trials for its new drug, Nidlegy, which is used to treat skin cancers. In the trial, Nidlegy demonstrated a statistically significant improvement in recurrence-free survival for patients with resectable melanoma. The study compared Nidlegy followed by surgery with surgery alone. The treatment arm showed a reduction in the hazard risk ratio, and treatment-related adverse events were reported to be benign and manageable. Nidlegy is also being developed for the treatment of other types of skin cancers. ....
Philogen Spa reported Monday that it purchased 6,855 of its own ordinary shares between June 12 and June 16. The shares were taken over at an average unit price of EUR16.2107, for a total value of. | June 19, 2023 ....
Philogen Spa announced Monday that it has bought back 3,290 of its own shares from May 29, 2023 to June 2, 2023. The shares were bought back at an average unit price of EUR15.6863, for a total. | June 5, 2023 ....
The Phase II clinical trial investigates Philogen's immunocytokines (i) L19IL2 (ii) L19TNF, and (iii) Nidlegy in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in stage III and IV ....
The companies have come together to commercialise Philogen s speciality product Nidlegy, an anti-cancer biopharmaceutical currently in Phase III clinical trials, Sun Pharma said in a statement. ....